Aftab Dana sold $2.2M of EXEL

Aftab Dana (EVP, Research and Development) sold 43,451 shares of EXELIXIS, INC. (EXEL) at $50.35 ($2.19M total) on 2026-05-26.

Original reporting
SEC EDGAR · Aftab Dana
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

Aftab Dana, EVP Research and Development, sold $2.19M of EXEL shares in an open-market transaction; the disclosure may slightly influence sentiment but does not introduce new operational or financial information about EXEL.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The absence of a stated 10b5-1 plan could raise speculation, but the filing provides no rationale for the sale or any link to upcoming catalysts.

Relevance 6/10Novelty 3/10Timing: Filed 2026-05-28, transaction dated 2026-05-26.

Background

The article is a SEC Form 4 insider transaction disclosure for EXELIXIS, Inc.

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

EXELIXIS Form 4 shows EVP R&D Aftab Dana sold 43,451 shares at $50.35 on 2026-05-26 for about $2.19M.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than thesis-changing.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales are often liquidity-driven and may not reflect negative expectations, especially without any other negative company-specific disclosures.

Key entities

  • EXELIXIS, INC.

    Company whose insider transaction is disclosed on Form 4.

  • Aftab Dana

    EVP, Research and Development who sold 43,451 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMedAI 8/10

Exelixis (EXEL) Q3 2026 Earnings Call Transcript

Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.

$EXELMed

Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum

Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.

$EXELMed

BMO raises Exelixis stock price target to $60 on OpEx outlook

BMO Capital raised Exelixis' (NASDAQ:EXEL) price target to $60 from $54, citing adjusted long-term operating expense assumptions. The stock trades near its 52-week high at $66.20, up 70% over the past year. Exelixis reported Q3 2026 earnings of $0.94 per share, beating estimates by 8.05%, with revenue of $658.69 million, a 1.81% beat. The company maintained its 2026 revenue guidance, attributing it to the gradual ramp of its NET product.